{"id":349326,"date":"2025-08-25T16:55:00","date_gmt":"2025-08-25T16:55:00","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-neurocrine-biosciences\/"},"modified":"2025-08-25T16:55:00","modified_gmt":"2025-08-25T16:55:00","slug":"how-to-buy-neurocrine-biosciences","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/","title":{"rendered":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-349326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Neurocrine Biosciences, Inc. (NBIX) hisseleri nas\u0131l al\u0131n\u0131r ve g\u00fc\u00e7l\u00fc 2025 performans\u0131 ile umut vadeden gelece\u011fe sahip bu b\u00fcy\u00fcyen n\u00f6robilim \u015firketine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Neurocrine Biosciences, Inc. (NBIX) hisseleri nas\u0131l al\u0131n\u0131r ve g\u00fc\u00e7l\u00fc 2025 performans\u0131 ile umut vadeden gelece\u011fe sahip bu b\u00fcy\u00fcyen n\u00f6robilim \u015firketine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r \u00f6\u011frenin."},"intro":"N\u00f6rolojik tedavilerde devrim yaratan bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Neurocrine Biosciences (NBIX), son teknoloji bilimi etkileyici finansal performansla birle\u015ftiriyor. Amiral gemisi ila\u00e7lar\u0131 INGREZZA rekor b\u00fcy\u00fcme g\u00f6sterirken ve yeni \u00fcr\u00fcnler ba\u015far\u0131yla piyasaya s\u00fcr\u00fcl\u00fcrken, bu biyoteknoloji lideri sa\u011fl\u0131k sekt\u00f6r\u00fcndeki patlamadan faydalanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in heyecan verici f\u0131rsatlar sunuyor.","intro_source":{"label":"Intro","type":"text","formatted_value":"N\u00f6rolojik tedavilerde devrim yaratan bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Neurocrine Biosciences (NBIX), son teknoloji bilimi etkileyici finansal performansla birle\u015ftiriyor. Amiral gemisi ila\u00e7lar\u0131 INGREZZA rekor b\u00fcy\u00fcme g\u00f6sterirken ve yeni \u00fcr\u00fcnler ba\u015far\u0131yla piyasaya s\u00fcr\u00fcl\u00fcrken, bu biyoteknoloji lideri sa\u011fl\u0131k sekt\u00f6r\u00fcndeki patlamadan faydalanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in heyecan verici f\u0131rsatlar sunuyor."},"body_html":"<h2>\ud83d\udcc8 NBIX Hisse Performans\u0131: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Neurocrine Biosciences (NBIX) hisseleri <strong>135,43 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse senedi, bu y\u0131l\u0131n ba\u015flar\u0131nda ya\u015fanan \u00f6nemli volatilitenin ard\u0131ndan dikkat \u00e7ekici bir diren\u00e7 g\u00f6sterdi ve yaz aylar\u0131 boyunca g\u00fc\u00e7l\u00fc bir toparlanma ivmesi sergiledi.<\/p> <p><strong>Takviminize Not Edin: 29 Ekim 2025<\/strong>, her NBIX yat\u0131r\u0131mc\u0131s\u0131n\u0131n takip etmesi gereken kritik tarih. \u015eirketin 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klad\u0131\u011f\u0131 bu tarihlerde, tarihsel olarak hisse senedi \u00f6nemli hareketler g\u00f6sterdi.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 NBIX Hisselerini Nas\u0131l Etkiler?<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>30 Temmuz 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>128,23 $<\/td><td><strong>%5,6 Art\u0131\u015f<\/strong> (Hisse Ba\u015f\u0131na Kazan\u00e7: 1,06 $ vs 0,98 $ tahmini)<\/td><\/tr> <tr><td>5 May\u0131s 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>110,50 $<\/td><td><strong>%7,8 Art\u0131\u015f<\/strong> (Gelir: 572,6M $ vs 560,97M $)<\/td><\/tr> <tr><td>\u015eubat 2025<\/td><td>Y\u00f6nlendirme G\u00fcncellemesi<\/td><td>153,90 $<\/td><td><strong>%21,8 D\u00fc\u015f\u00fc\u015f<\/strong> (B\u00fcy\u00fcme e\u011frisi endi\u015feleri)<\/td><\/tr> <tr><td>Kas\u0131m 2024<\/td><td>\u00dcr\u00fcn Lansman\u0131<\/td><td>125,80 $<\/td><td><strong>%4,2 Art\u0131\u015f<\/strong> (CRENESSITY ilk ba\u015far\u0131s\u0131)<\/td><\/tr> <tr><td>A\u011fustos 2024<\/td><td>2. \u00c7eyrek 2024<\/td><td>119,00 $<\/td><td><strong>%6,8 D\u00fc\u015f\u00fc\u015f<\/strong> (Klinik deneme endi\u015feleri)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Analizi<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle NBIX'i birka\u00e7 g\u00fcn i\u00e7inde %5-8 art\u0131r\u0131rken, olumsuz klinik haberler keskin %20+ d\u00fc\u015f\u00fc\u015flere neden olabilir. Bu model, bu hissenin sabr\u0131 \u00f6d\u00fcllendirdi\u011fini ancak pozitif kataliz\u00f6rler s\u0131ras\u0131nda teredd\u00fct\u00fc cezaland\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>NBIX hisseleri bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131 ancak bu d\u00f6nemde <strong>%15,2<\/strong> kazan\u00e7 sa\u011flad\u0131:<\/p> <p><strong>\u015eubat<\/strong>: 153,90 $ (y\u0131l\u0131n en y\u00fcksek seviyesi, ard\u0131ndan y\u00f6nlendirme endi\u015feleri nedeniyle keskin d\u00fc\u015f\u00fc\u015f)<br\/> <strong>Mart<\/strong>: 119,00 $ (\u015eubat sat\u0131\u015f\u0131ndan sonra stabilizasyon)<br\/> <strong>Nisan<\/strong>: 84,23 $ (y\u0131l\u0131n en d\u00fc\u015f\u00fck seviyesi - rekabet bask\u0131lar\u0131na piyasa a\u015f\u0131r\u0131 tepkisi)<br\/> <strong>May\u0131s<\/strong>: 123,02 $ (1. \u00e7eyrek kazan\u00e7 s\u00fcrprizinden sonra g\u00fc\u00e7l\u00fc toparlanma)<br\/> <strong>Haziran<\/strong>: 125,69 $ (Medicare kapsam geni\u015flemesinden devam eden momentum)<br\/> <strong>Temmuz<\/strong>: 128,23 $ (2. \u00e7eyrek kazan\u00e7 heyecan\u0131 art\u0131yor)<br\/> <strong>A\u011fustos<\/strong>: 135,43 $ (mevcut seviye - s\u00fcrd\u00fcr\u00fclen toparlanma)<\/p> <p><strong>Toparlanman\u0131n Sebepleri?<\/strong><\/p> <ul> <li>INGREZZA rekor hasta ba\u015flang\u0131\u00e7lar\u0131 ger\u00e7ekle\u015ftirdi<\/li> <li>Medicare B\u00f6l\u00fcm D kapsam\u0131 dramatik \u015fekilde geni\u015fledi<\/li> <li>CRENESSITY lansman\u0131 beklentileri a\u015ft\u0131 ve ilk \u00e7eyrekte 15M $ sat\u0131\u015f yapt\u0131<\/li> <li>May\u0131s ve Haziran boyunca analist y\u00fckseltmeleri geldi<\/li> <\/ul> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Y\u0131l Sonu<\/strong>: 162-175 $ (mevcut momentum ve 3. & 4. \u00e7eyrek beklentilerine g\u00f6re) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br\/> <strong>2026 Projeksiyonu<\/strong>: 190-210 $ (INGREZZA pazar hakimiyeti + \u00fcr\u00fcn hatt\u0131 ilerlemesi)<br\/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 250-280 $ (yeni \u00fcr\u00fcn lansmanlar\u0131 + uluslararas\u0131 geni\u015fleme)<br\/> <strong>2030 Vizyonu<\/strong>: 350+ $ (n\u00f6roloji pazar liderli\u011fi + potansiyel blockbuster ila\u00e7lar)<\/p> <p><strong>Sonu\u00e7<\/strong>: Hem k\u0131sa vadeli yat\u0131r\u0131mc\u0131lar hem de uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>AL<\/strong> tavsiyesi. G\u00fc\u00e7l\u00fc mevcut performans ve umut vadeden \u00fcr\u00fcn hatt\u0131 kombinasyonu NBIX'i b\u00fcy\u00fcme i\u00e7in ola\u011fan\u00fcst\u00fc konuma getiriyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong> - \u015eizofreni program\u0131 2024'te rakiplerin gerisinde kald\u0131<\/li> <li><strong>FDA d\u00fczenleyici engelleri<\/strong> - Yeni ila\u00e7 onaylar\u0131ndaki gecikmeler b\u00fcy\u00fcmeyi etkileyebilir<\/li> <li><strong>Rekabet bask\u0131lar\u0131<\/strong> - Benzer n\u00f6rolojik tedaviler geli\u015ftiren di\u011fer \u015firketler<\/li> <li><strong>Volatilite<\/strong> - Biyoteknoloji hisseleri tek haber olay\u0131nda %20+ dalgalanabilir<\/li> <li><strong>Patent s\u00fcresi dolmalar\u0131<\/strong> - INGREZZA'n\u0131n m\u00fcnhas\u0131rl\u0131\u011f\u0131 i\u00e7in uzun vadeli endi\u015fe<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Kazan\u00e7 s\u00fcrprizleri<\/strong> - Analist beklentilerini s\u00fcrekli a\u015fmak<\/li> <li><strong>Rekor sat\u0131\u015f b\u00fcy\u00fcmesi<\/strong> - INGREZZA 2. \u00e7eyrekte %15 art\u0131\u015f g\u00f6sterdi<\/li> <li><strong>Yeni \u00fcr\u00fcn ba\u015far\u0131s\u0131<\/strong> - CRENESSITY ilk tam \u00e7eyrekte 15M $ sat\u0131\u015f yapt\u0131<\/li> <li><strong>Analist y\u00fckseltmeleri<\/strong> - 2025 boyunca bir\u00e7ok firma fiyat hedeflerini y\u00fckseltti<\/li> <li><strong>Pazar geni\u015flemesi<\/strong> - Medicare kapsam\u0131 yeni hasta kazan\u0131m\u0131n\u0131 destekliyor<\/li> <li><strong>G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131<\/strong> - Ge\u00e7 a\u015fama geli\u015ftirmede birden fazla aday<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Rahat oldu\u011funuz bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n (portf\u00f6y\u00fcn %5-10'u maksimum)<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 kullan\u0131n<\/strong> - T\u00fcm\u00fcn\u00fc bir kerede almak yerine par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> - Daha iyi giri\u015f noktalar\u0131 i\u00e7in 130 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015fleri takip edin<\/li> <li><strong>29 Ekim'i izleyin<\/strong> - Momentum devam ederse 3. \u00e7eyrek kazan\u00e7lar\u0131ndan \u00f6nce al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Esprili yakla\u015f\u0131m<\/strong>: \"NBIX ticareti n\u00f6rolojik tedavi gibidir - bazen faydalar\u0131 g\u00f6rmeden \u00f6nce yan etkilerle sabretmeniz gerekir!\"<\/li> <\/ol> <h2>\u2705 Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>NBIX'i detayl\u0131 ara\u015ft\u0131r\u0131n<\/td><td>\u015eirketin \u00fcr\u00fcnlerini ve risklerini anlay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Limitli emir verin<\/td><td>A\u015f\u0131r\u0131 \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 takip edin<\/td><td>Kazan\u00e7 tarihlerini ve sekt\u00f6r haberlerini d\u00fczenli izleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, NBIX hisseleri ticareti konusunda birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum depozito: 5 $<\/strong> - Minimal riskle stratejileri test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Basit belge y\u00fckleme ile dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> - Karlar\u0131n\u0131za \u00e7e\u015fitli kolay y\u00f6ntemlerle eri\u015fin<\/li> <li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> - Hisse senedi ticaretini \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in sezgisel aray\u00fcz<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Neurocrine Biosciences: N\u00f6robilimde Yenilik Lideri<\/h2> <p>Neurocrine Biosciences, tek \u00fcr\u00fcnl\u00fc bir \u015firketten \u00e7e\u015fitlendirilmi\u015f bir n\u00f6robilim g\u00fcc\u00fcne d\u00f6n\u00fc\u015ft\u00fc. INGREZZA 2025 2. \u00e7eyrekte 624 milyon dolar\u0131n \u00fczerinde sat\u0131\u015f yaparken ve CRENESSITY g\u00fc\u00e7l\u00fc erken benimseme g\u00f6sterirken, \u015firket ba\u015far\u0131l\u0131 bir \u015fekilde \"\u00e7oklu blockbuster n\u00f6robilim \u015firketi\" haline geldi.<\/p> <p>\u015eirket, \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar ve b\u00fcy\u00fck b\u00fcy\u00fcme potansiyeline sahip karma\u015f\u0131k n\u00f6rolojik, n\u00f6roendokrin ve n\u00f6ropsikiyatrik bozukluklar i\u00e7in tedaviler geli\u015ftirmeye odaklan\u0131yor. AbbVie ve Mitsubishi Tanabe Pharma gibi sekt\u00f6r devleriyle stratejik i\u015f birlikleri, bilimsel yakla\u015f\u0131mlar\u0131n\u0131n ek do\u011frulamas\u0131n\u0131 sa\u011fl\u0131yor.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Neurocrine ara\u015ft\u0131rma ekibi, ila\u00e7 geli\u015ftirme s\u00fcrecinde haftal\u0131k 5.000'den fazla molek\u00fcler bile\u015fi\u011fi analiz ediyor ancak genellikle sadece 1-2'si klinik denemelere ilerliyor - bu da modern ila\u00e7 geli\u015ftirmedeki zorluk ve hassasiyeti g\u00f6steriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 NBIX Hisse Performans\u0131: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Neurocrine Biosciences (NBIX) hisseleri <strong>135,43 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse senedi, bu y\u0131l\u0131n ba\u015flar\u0131nda ya\u015fanan \u00f6nemli volatilitenin ard\u0131ndan dikkat \u00e7ekici bir diren\u00e7 g\u00f6sterdi ve yaz aylar\u0131 boyunca g\u00fc\u00e7l\u00fc bir toparlanma ivmesi sergiledi.<\/p>\n<p><strong>Takviminize Not Edin: 29 Ekim 2025<\/strong>, her NBIX yat\u0131r\u0131mc\u0131s\u0131n\u0131n takip etmesi gereken kritik tarih. \u015eirketin 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klad\u0131\u011f\u0131 bu tarihlerde, tarihsel olarak hisse senedi \u00f6nemli hareketler g\u00f6sterdi.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 NBIX Hisselerini Nas\u0131l Etkiler?<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>30 Temmuz 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>128,23 $<\/td>\n<td><strong>%5,6 Art\u0131\u015f<\/strong> (Hisse Ba\u015f\u0131na Kazan\u00e7: 1,06 $ vs 0,98 $ tahmini)<\/td>\n<\/tr>\n<tr>\n<td>5 May\u0131s 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>110,50 $<\/td>\n<td><strong>%7,8 Art\u0131\u015f<\/strong> (Gelir: 572,6M $ vs 560,97M $)<\/td>\n<\/tr>\n<tr>\n<td>\u015eubat 2025<\/td>\n<td>Y\u00f6nlendirme G\u00fcncellemesi<\/td>\n<td>153,90 $<\/td>\n<td><strong>%21,8 D\u00fc\u015f\u00fc\u015f<\/strong> (B\u00fcy\u00fcme e\u011frisi endi\u015feleri)<\/td>\n<\/tr>\n<tr>\n<td>Kas\u0131m 2024<\/td>\n<td>\u00dcr\u00fcn Lansman\u0131<\/td>\n<td>125,80 $<\/td>\n<td><strong>%4,2 Art\u0131\u015f<\/strong> (CRENESSITY ilk ba\u015far\u0131s\u0131)<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2024<\/td>\n<td>2. \u00c7eyrek 2024<\/td>\n<td>119,00 $<\/td>\n<td><strong>%6,8 D\u00fc\u015f\u00fc\u015f<\/strong> (Klinik deneme endi\u015feleri)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Analizi<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle NBIX&#8217;i birka\u00e7 g\u00fcn i\u00e7inde %5-8 art\u0131r\u0131rken, olumsuz klinik haberler keskin %20+ d\u00fc\u015f\u00fc\u015flere neden olabilir. Bu model, bu hissenin sabr\u0131 \u00f6d\u00fcllendirdi\u011fini ancak pozitif kataliz\u00f6rler s\u0131ras\u0131nda teredd\u00fct\u00fc cezaland\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>NBIX hisseleri bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131 ancak bu d\u00f6nemde <strong>%15,2<\/strong> kazan\u00e7 sa\u011flad\u0131:<\/p>\n<p><strong>\u015eubat<\/strong>: 153,90 $ (y\u0131l\u0131n en y\u00fcksek seviyesi, ard\u0131ndan y\u00f6nlendirme endi\u015feleri nedeniyle keskin d\u00fc\u015f\u00fc\u015f)<br \/> <strong>Mart<\/strong>: 119,00 $ (\u015eubat sat\u0131\u015f\u0131ndan sonra stabilizasyon)<br \/> <strong>Nisan<\/strong>: 84,23 $ (y\u0131l\u0131n en d\u00fc\u015f\u00fck seviyesi &#8211; rekabet bask\u0131lar\u0131na piyasa a\u015f\u0131r\u0131 tepkisi)<br \/> <strong>May\u0131s<\/strong>: 123,02 $ (1. \u00e7eyrek kazan\u00e7 s\u00fcrprizinden sonra g\u00fc\u00e7l\u00fc toparlanma)<br \/> <strong>Haziran<\/strong>: 125,69 $ (Medicare kapsam geni\u015flemesinden devam eden momentum)<br \/> <strong>Temmuz<\/strong>: 128,23 $ (2. \u00e7eyrek kazan\u00e7 heyecan\u0131 art\u0131yor)<br \/> <strong>A\u011fustos<\/strong>: 135,43 $ (mevcut seviye &#8211; s\u00fcrd\u00fcr\u00fclen toparlanma)<\/p>\n<p><strong>Toparlanman\u0131n Sebepleri?<\/strong><\/p>\n<ul>\n<li>INGREZZA rekor hasta ba\u015flang\u0131\u00e7lar\u0131 ger\u00e7ekle\u015ftirdi<\/li>\n<li>Medicare B\u00f6l\u00fcm D kapsam\u0131 dramatik \u015fekilde geni\u015fledi<\/li>\n<li>CRENESSITY lansman\u0131 beklentileri a\u015ft\u0131 ve ilk \u00e7eyrekte 15M $ sat\u0131\u015f yapt\u0131<\/li>\n<li>May\u0131s ve Haziran boyunca analist y\u00fckseltmeleri geldi<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 162-175 $ (mevcut momentum ve 3. &#038; 4. \u00e7eyrek beklentilerine g\u00f6re) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> <strong>2026 Projeksiyonu<\/strong>: 190-210 $ (INGREZZA pazar hakimiyeti + \u00fcr\u00fcn hatt\u0131 ilerlemesi)<br \/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 250-280 $ (yeni \u00fcr\u00fcn lansmanlar\u0131 + uluslararas\u0131 geni\u015fleme)<br \/> <strong>2030 Vizyonu<\/strong>: 350+ $ (n\u00f6roloji pazar liderli\u011fi + potansiyel blockbuster ila\u00e7lar)<\/p>\n<p><strong>Sonu\u00e7<\/strong>: Hem k\u0131sa vadeli yat\u0131r\u0131mc\u0131lar hem de uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>AL<\/strong> tavsiyesi. G\u00fc\u00e7l\u00fc mevcut performans ve umut vadeden \u00fcr\u00fcn hatt\u0131 kombinasyonu NBIX&#8217;i b\u00fcy\u00fcme i\u00e7in ola\u011fan\u00fcst\u00fc konuma getiriyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong> &#8211; \u015eizofreni program\u0131 2024&#8217;te rakiplerin gerisinde kald\u0131<\/li>\n<li><strong>FDA d\u00fczenleyici engelleri<\/strong> &#8211; Yeni ila\u00e7 onaylar\u0131ndaki gecikmeler b\u00fcy\u00fcmeyi etkileyebilir<\/li>\n<li><strong>Rekabet bask\u0131lar\u0131<\/strong> &#8211; Benzer n\u00f6rolojik tedaviler geli\u015ftiren di\u011fer \u015firketler<\/li>\n<li><strong>Volatilite<\/strong> &#8211; Biyoteknoloji hisseleri tek haber olay\u0131nda %20+ dalgalanabilir<\/li>\n<li><strong>Patent s\u00fcresi dolmalar\u0131<\/strong> &#8211; INGREZZA&#8217;n\u0131n m\u00fcnhas\u0131rl\u0131\u011f\u0131 i\u00e7in uzun vadeli endi\u015fe<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Kazan\u00e7 s\u00fcrprizleri<\/strong> &#8211; Analist beklentilerini s\u00fcrekli a\u015fmak<\/li>\n<li><strong>Rekor sat\u0131\u015f b\u00fcy\u00fcmesi<\/strong> &#8211; INGREZZA 2. \u00e7eyrekte %15 art\u0131\u015f g\u00f6sterdi<\/li>\n<li><strong>Yeni \u00fcr\u00fcn ba\u015far\u0131s\u0131<\/strong> &#8211; CRENESSITY ilk tam \u00e7eyrekte 15M $ sat\u0131\u015f yapt\u0131<\/li>\n<li><strong>Analist y\u00fckseltmeleri<\/strong> &#8211; 2025 boyunca bir\u00e7ok firma fiyat hedeflerini y\u00fckseltti<\/li>\n<li><strong>Pazar geni\u015flemesi<\/strong> &#8211; Medicare kapsam\u0131 yeni hasta kazan\u0131m\u0131n\u0131 destekliyor<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131<\/strong> &#8211; Ge\u00e7 a\u015fama geli\u015ftirmede birden fazla aday<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Rahat oldu\u011funuz bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n (portf\u00f6y\u00fcn %5-10&#8217;u maksimum)<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 kullan\u0131n<\/strong> &#8211; T\u00fcm\u00fcn\u00fc bir kerede almak yerine par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> &#8211; Daha iyi giri\u015f noktalar\u0131 i\u00e7in 130 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015fleri takip edin<\/li>\n<li><strong>29 Ekim&#8217;i izleyin<\/strong> &#8211; Momentum devam ederse 3. \u00e7eyrek kazan\u00e7lar\u0131ndan \u00f6nce al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Esprili yakla\u015f\u0131m<\/strong>: &#8220;NBIX ticareti n\u00f6rolojik tedavi gibidir &#8211; bazen faydalar\u0131 g\u00f6rmeden \u00f6nce yan etkilerle sabretmeniz gerekir!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>NBIX&#8217;i detayl\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>\u015eirketin \u00fcr\u00fcnlerini ve risklerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limitli emir verin<\/td>\n<td>A\u015f\u0131r\u0131 \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 takip edin<\/td>\n<td>Kazan\u00e7 tarihlerini ve sekt\u00f6r haberlerini d\u00fczenli izleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, NBIX hisseleri ticareti konusunda birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito: 5 $<\/strong> &#8211; Minimal riskle stratejileri test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Basit belge y\u00fckleme ile dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; Karlar\u0131n\u0131za \u00e7e\u015fitli kolay y\u00f6ntemlerle eri\u015fin<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> &#8211; Hisse senedi ticaretini \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in sezgisel aray\u00fcz<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Neurocrine Biosciences: N\u00f6robilimde Yenilik Lideri<\/h2>\n<p>Neurocrine Biosciences, tek \u00fcr\u00fcnl\u00fc bir \u015firketten \u00e7e\u015fitlendirilmi\u015f bir n\u00f6robilim g\u00fcc\u00fcne d\u00f6n\u00fc\u015ft\u00fc. INGREZZA 2025 2. \u00e7eyrekte 624 milyon dolar\u0131n \u00fczerinde sat\u0131\u015f yaparken ve CRENESSITY g\u00fc\u00e7l\u00fc erken benimseme g\u00f6sterirken, \u015firket ba\u015far\u0131l\u0131 bir \u015fekilde &#8220;\u00e7oklu blockbuster n\u00f6robilim \u015firketi&#8221; haline geldi.<\/p>\n<p>\u015eirket, \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar ve b\u00fcy\u00fck b\u00fcy\u00fcme potansiyeline sahip karma\u015f\u0131k n\u00f6rolojik, n\u00f6roendokrin ve n\u00f6ropsikiyatrik bozukluklar i\u00e7in tedaviler geli\u015ftirmeye odaklan\u0131yor. AbbVie ve Mitsubishi Tanabe Pharma gibi sekt\u00f6r devleriyle stratejik i\u015f birlikleri, bilimsel yakla\u015f\u0131mlar\u0131n\u0131n ek do\u011frulamas\u0131n\u0131 sa\u011fl\u0131yor.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Neurocrine ara\u015ft\u0131rma ekibi, ila\u00e7 geli\u015ftirme s\u00fcrecinde haftal\u0131k 5.000&#8217;den fazla molek\u00fcler bile\u015fi\u011fi analiz ediyor ancak genellikle sadece 1-2&#8217;si klinik denemelere ilerliyor &#8211; bu da modern ila\u00e7 geli\u015ftirmedeki zorluk ve hassasiyeti g\u00f6steriyor.<\/p>\n"},"faq":[{"question":"Neurocrine Biosciences hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, NBIX hakk\u0131nda ara\u015ft\u0131rma yap\u0131n, limitli emir verin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak takip edin."},{"question":"NBIX hisselerinin 2025 sonu fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in NBIX hisseleri 162-175 $ aral\u0131\u011f\u0131nda tahmin edilmekte olup, g\u00fc\u00e7l\u00fc al\u0131m \u00f6nerilmektedir."},{"question":"NBIX hisseleri i\u00e7in temel riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay gecikmeleri, rekabet bask\u0131lar\u0131, y\u00fcksek volatilite ve patent s\u00fcresi dolmalar\u0131 temel riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar NBIX hisseleri i\u00e7in nas\u0131l bir strateji izlemeli?","answer":"K\u00fc\u00e7\u00fck ba\u015flayarak, dolar maliyeti ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurarak ve \u00f6nemli kazan\u00e7 tarihlerini takip ederek yat\u0131r\u0131m yapmalar\u0131 \u00f6nerilir."},{"question":"Pocket Option NBIX hisseleri i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu para \u00e7ekme se\u00e7enekleri ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Neurocrine Biosciences hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, NBIX hakk\u0131nda ara\u015ft\u0131rma yap\u0131n, limitli emir verin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak takip edin."},{"question":"NBIX hisselerinin 2025 sonu fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in NBIX hisseleri 162-175 $ aral\u0131\u011f\u0131nda tahmin edilmekte olup, g\u00fc\u00e7l\u00fc al\u0131m \u00f6nerilmektedir."},{"question":"NBIX hisseleri i\u00e7in temel riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay gecikmeleri, rekabet bask\u0131lar\u0131, y\u00fcksek volatilite ve patent s\u00fcresi dolmalar\u0131 temel riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar NBIX hisseleri i\u00e7in nas\u0131l bir strateji izlemeli?","answer":"K\u00fc\u00e7\u00fck ba\u015flayarak, dolar maliyeti ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurarak ve \u00f6nemli kazan\u00e7 tarihlerini takip ederek yat\u0131r\u0131m yapmalar\u0131 \u00f6nerilir."},{"question":"Pocket Option NBIX hisseleri i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu para \u00e7ekme se\u00e7enekleri ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T16:55:00+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T16:55:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/\",\"name\":\"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"datePublished\":\"2025-08-25T16:55:00+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/","og_locale":"tr_TR","og_type":"article","og_title":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T16:55:00+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T16:55:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/","name":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","datePublished":"2025-08-25T16:55:00+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Neurocrine Biosciences, Inc. (NBIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurocrine Biosciences, Inc. (NBIX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":349327,"slug":"how-to-buy-neurocrine-biosciences","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Neurocrine Biosciences, Inc. (NBIX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Neurocrine Biosciences, Inc. (NBIX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/"},"pt_AA":{"locale":"pt_AA","id":349323,"slug":"how-to-buy-neurocrine-biosciences","post_title":"Como comprar a\u00e7\u00f5es da Neurocrine Biosciences, Inc. (NBIX) - Investimento em a\u00e7\u00f5es da Neurocrine Biosciences, Inc. (NBIX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-neurocrine-biosciences\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=349326"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349326\/revisions"}],"predecessor-version":[{"id":349330,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349326\/revisions\/349330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334018"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=349326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=349326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=349326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}